31 January 2025 in Medicine
Background: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare, life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, elevated liver enzymes, and acute kidney injury. Prompt diagnosis and therapy are crucial due to the high risk of progression to chronic kidney disease (CKD), end-stage kidney disease (ESKD), and dialysis dependency, as well as significant maternal and fetal morbidity and mortality. Methods: A comprehensive literature search was conducted across EMBASE, MEDLINE, and the Cochrane CENTRAL from January 2000 to March 2024. Studies reporting on pregnancy and kidney outcomes in women diagnosed with p-aHUS were included. Results: Ten studies involving 386 pregnancies in 380 patients met the inclusion criteria for the final analysis. Renal outcomes varied, with mean creatinine levels ranging from 0.72 to 8.734 mg/dL. Dialysis was required in 66.6% of patients, and 25% developed ESKD. Maternal complications included preeclampsia (36.4%) and hemolysis, elevated liver enzymes, and low platelets syndrome (29.7%), with a 5% maternal mortality rate. Fetal complications included intrauterine fetal demise (n = 25), intrauterine growth restriction, low birth weight, and prematurity. Treatment with eculizumab significantly reduced the risk of CKD and ESKD, with a pooled risk ratio of 0.20 (95% confidence interval: 0.09–0.44) and low heterogeneity (I² = 0%, P = .43). Conclusion: This analysis highlights the severe kidney and pregnancy outcomes associated with p-aHUS. Eculizumab treatment is significantly beneficial in reducing the risk of CKD and ESKD.
30 December 2022 in Nepalese Medical Journal
Introduction: The government of Nepal has been providing free dialysis for a lifetime to its citizen since 2016. Most of the patients have to spend from pocket to meet their medical demands to sustain life. This leads to a financial burden and may lead to the sale of the property. The aim of this was study to look into different categories of expenses done by patients in the Bipanna nagarik free HD program provided by the government of Nepal.Materials and Methods: This descriptive cross-sectional study was carried out from 9th February 2022 till 30th September 2022 under the Nephrology Unit, Department of Internal Medicine at Universal College of Medical Sciences, Bhairahawa, Nepal. Ethical clearance was taken from the Institutional Review Committee (IRC letter reference no. UCMS/IRC/049/22). Patients receiving free basic hemodialysis services under the Bippana Nagarik Scheme of the Government of Nepal and giving informed and written consent were enrolled in the study. Non-Probability Sampling Method – Convenience Sampling was done.Results: In our study of 50 patients on HD, the mean age was 46.24 ± 15.31 years. The mean duration of dialysis of the study population was 126.80 ± 332.52 months. The average family income per annum was approximately NRs. 31000. The total out-of-pocket expenditure was approximately NRs. 35305/month. The cost of blood investigations was approximately NRs. 13000 in three months.Conclusion: The monthly out of pocket expenditure was approximately NRs. 35000 which was directly related to hemodialysis in spite of free basic hemodialysis services by the Government of Nepal.